VRTX surged 24.2% over the past 30 days, driven by renewed investor confidence in its pipeline. The stock's quarterly gain of approximately 9.9% reflects a steady uptrend that accelerated in late June.

Arm Holdings shares declined approximately 23% over the past 30 days, falling from $411.83 on June 3 to $315.50, as a broad AI-sector rotation triggered heavy profit-taking in high-multiple semiconductor names. The selloff was driven primarily by valuation concerns and sector-wide de-risking rather than company-specific fundamental deterioration, with a Korean-led chip rout accelerating the pullback in late June.

TotalEnergies shares fell approximately 14.2% over the last 30 days, driven primarily by a sharp decline in crude oil prices following the US-Iran peace deal and the reopening of the Strait of Hormuz. Brent crude dropped from elevated levels above $110 per barrel in May to the low $70s by early July, removing a substantial geopolitical risk premium that had supported energy stocks.

Novo Nordisk (NVO) shares surged approximately 20% over the last 30 days, climbing from $42.00 to $50.43. The broader quarterly performance was even stronger, with the stock gaining roughly 38% since early April.

AAOI shares plunged approximately 40.2% over the past 30 days, falling from $202.37 on June 2, 2026, to $120.94 on July 2, 2026. The sharp decline follows a period of extreme volatility and profit-taking after the stock surged more than 130% earlier in the quarter.

Alcoa shares plunged approximately 39.8% over the past 30 days, falling from $80.86 on June 3 to $48.68 on July 2, 2026. A sharply negative Q2 operating update on June 10, in which management flagged a roughly $60 million unfavorable hit to Alumina segment adjusted EBITDA, triggered the initial selloff.

HPE shares have declined approximately 26.6% over the past 30 days, falling from $56.15 on June 2 to $41.20 on July 2, 2026. The pullback follows a massive post-earnings surge in early June, when the stock hit a multi-year high of $64.25 after reporting blockbuster fiscal Q2 2026 results.

IREN shares plunged approximately 41.7% over the past 30 days, falling from $66.60 on June 2 to $38.83 as of July 2, 2026, erasing billions in market capitalization. A sharp decline in Bitcoin below $60,000, combined with broader AI spending concerns that hit the Nasdaq and semiconductor stocks, triggered heavy selling across crypto-linked and AI infrastructure names.

CRCL shares fell approximately 28% over the past 30 days, driven by a sharp selloff following the announcement of a new competing stablecoin network. The launch of Open USD (OUSD), backed by Visa and other major financial institutions, intensified competitive fears and triggered a single-day decline of over 17% on June 30.

IonQ shares fell approximately 31.2% over the past 30 days, dropping from $71.40 on June 2 to $49.12 on July 2, as a sharp reversal from the stock's multi-month rally took hold. Insider selling by multiple directors and executives during June amplified valuation concerns, with the stock trading at roughly 97 times trailing sales despite heavy operating losses.

Lindsay Corporation reported Q3 fiscal 2026 revenue of $160.8 million, down 5% year-over-year. Diluted EPS came in at $1.53, beating analyst consensus estimates.

Glaukos Corporation (GKOS) surged approximately 33.9% over the last 30 days, climbing from $110.78 on June 2, 2026, to $148.34 on July 2, 2026, and reaching a new 52-week high. The rally was fueled by a combination of a landmark reimbursement milestone for Epioxa, a pipeline advancement with GLK-321, and sustained commercial momentum from iDose TR.

TG Therapeutics (TGTX) surged approximately 45.7% over the last 30 days, climbing from $36.64 on June 2 to $53.37 by July 2, 2026. The rally extended a powerful quarterly uptrend, with the stock gaining roughly 59% since the start of April 2026.

Alkermes shares surged approximately 27.6% over the past 30 days, climbing from $42.76 on June 3 to $54.57 as of July 2, 2026, driven by a series of positive clinical and regulatory catalysts for its lead orexin agonist, alixorexton. The stock has gained roughly 56% over the last quarter, reflecting mounting investor confidence in the company's expanding neuroscience pipeline and sleep-medicine franchise.

Kymera Therapeutics shares surged approximately 55.1% over the last 30 days, driven by a series of positive clinical and corporate catalysts. The pivotal event was the early completion of enrollment in the Phase 2b BROADEN2 trial for KT-621 in atopic dermatitis, accelerating the topline data readout to year-end 2026.

Compass Inc. (COMP) shares surged approximately 66% over the past 30 days, climbing from $7.61 on June 3 to $12.62 by July 2, 2026.

Apogee Therapeutics shares surged approximately 68.9% over the past 30 days, driven almost entirely by AbbVie's announced $10.9 billion all-cash acquisition. AbbVie agreed to pay $135.11 per share, representing a 49.5% premium to Apogee's closing price before the deal was revealed.

Bio-Techne shares surged approximately 42.3% over the last 30 days, driven overwhelmingly by Merck KGaA's announced $73-per-share all-cash acquisition. The $11.3 billion enterprise value deal, unveiled on June 25, 2026, represented a 24% premium to Bio-Techne's prior closing price and triggered a single-day rally of roughly 20%.

Moderna shares surged approximately 74.9% over the past 30 days, climbing from $45.64 on June 2 to $79.80 by July 2, 2026, driven by a series of powerful pipeline and regulatory catalysts. A unanimous 9-0 FDA advisory committee vote in favor of the company's mRNA-1010 flu vaccine candidate dramatically de-risked a key commercial opportunity ahead of the August 5 PDUFA decision.

Astera Labs (ALAB) shares climbed approximately 14% over the past 30 days, extending a powerful multi-month rally driven by AI infrastructure demand. Nasdaq-100 index inclusion, effective June 22, triggered mandatory buying from passive funds and ETFs tracking the benchmark, adding sustained upward pressure.